Haven't used Prota Therapeutics yet?
Ask AI

Ask AI about Prota Therapeutics

Generated with AI from 10 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Questions & Answers

No questions yet β€” be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website β€” its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="protatherapeutics-com" data-lang="en"></div>
More widgets

About Prota Therapeutics

Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel combination probiotic allergen oral immunotherapy treatments. Prota holds an exclusive license to the patented probiotic food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures' Healthcare Fund III) – including $5M from the Australian Commonwealth Government Biomedical Translation Fund – as well as private investment. This has enabled Prota to advance their clinical program, develop scalable cGMP product manufacturing processes, and initiate discussions with regulatory agencies in the lead up to a planned large-scale pivotal Phase 3 efficacy and safety study for the PRT100 peanut allergy treatment.